Astellas Pharma's book value per share for the quarter that ended in Mar. 2026 was $6.43.
During the past 12 months, Astellas Pharma's average Book Value Per Share Growth Rate was 20.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Astellas Pharma was 10.90% per year. The lowest was 1.10% per year. And the median was 4.25% per year.
Astellas Pharma's current price is $12.85. Its book value per share for the quarter that ended in Mar. 2026 was $6.43. Hence, today's PB Ratio of Astellas Pharma is 2.00.
During the past 13 years, the highest P/B Ratio of Astellas Pharma was 3.05. The lowest was 1.50. And the median was 2.31.
Astellas Pharma (OTCPK:ALPMF) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Astellas Pharma Book Value per Share Related Terms
Astellas Pharma Book Value per Share Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: Book Value per Share Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Book Value per Share of $6.43 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Book Value per Share too high?
Astellas Pharma's current Book Value per Share is $6.43. Overall, Astellas Pharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Book Value per Share compare to LLY and JNJ?
Astellas Pharma's Book Value per Share of $6.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Book Value per Share is $6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.19, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current Book Value per Share is $6.43. Astellas Pharma's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Book Value per Share is $6.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.19.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Book Value per Share: $6.43
GF Value™: $14.19 vs. price of $12.85 (9.4% below fair value)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
72GF Score
Get the complete analysis for ALPMF
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
